The inhibition of the AChE enzyme using specific inhibitors has emerged as a promising therapeutic approach for managing a range of neurological disorders including Lewy body dementia and Alzheimer’s disease (AD) [1,2]. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.